

Aoxing Pharmaceutical Company, Inc.

Room 1517 Nam Fung Centre
264-298 Castle Peak Rd
Tsuen Wan 000000
Hong Kong

+852 9491-2348

frankiecflo@outlook.com

Supplemental Report: Catch All Information

The information provided below is designed to encompass the "Catch All" information required in Rule 15c2-11.

1. The name of the issuer and any predecessors during the past five years;
Aoxing Pharmaceutical Company, Inc.
2. The address(es) of the issuer's principal executive office and of its principal place of business;

Room 1517 Nam Fung Centre
264-298 Castle Peak Rd
Tsuen Wan 000000
Hong Kong

3. The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years;

Current State and Date of Incorporation or Registration: FL, incorporated on 1/23/1996
Standing in this jurisdiction: (e.g. active, default, inactive): Active

4. The title, class, and ticker symbol (if assigned) of the security:

Trading symbol:	AOXG
Exact title and class of securities outstanding:	Common
CUSIP:	03740A106
Par or stated value:	0.0001

5. The number of shares or total amount of the securities outstanding as of the end of the issuer's most recent fiscal year;

Total shares outstanding: 381,209,195 as of date: June 30, 2025

6. The name and address of the transfer agent;

Name: Olde Monmouth Stock Transfer CO., Inc.
 Phone: (732) 872-2727
 Email: matt@oldemonmouth.com
 Address: 200 Memorial Pkwy, Atlantic Heights, NJ 07716

7. A description of the issuer's business;

The goal of this disclosure is to provide information with respect to the company's acquisition of Hong Kong's InfoEd Tech Limited and a complete strategic shift from pharmaceutical development to Educational Technology (EdTech).

On June 18, 2025, Aoxing Pharmaceutical Company, Inc. acquired Hong Kong's InfoEd Tech Limited, a premier educational technology firm for \$450,000 USD. The acquisition of InfoEd Tech Limited aligns with AOXG's mission to provide high-quality educational resources tailored to the diverse linguistic landscape of the Asia Pacific. Dr. Lo's extensive experience as a trainer has revealed that language barriers significantly hinder learning opportunities for many citizens in the region. By converting training programs into video formats and utilizing AI for multilingual support, AOXG aims to democratize access to education, enabling learners to benefit from global expertise.

As part of this transition, AOXG will discontinue its previous operations in the development, manufacturing, and marketing of active pharmaceutical ingredients for narcotics and neurological drugs. Instead, the company will focus on providing innovative educational technology solutions aimed at overcoming language barriers in the Asia Pacific region.

8. A description of products or services offered by the issuer;

Educational Technology (EdTech)

9. A description and extent of the issuer's facilities;

Office Building located at:
 Room 1517 Nam Fung Centre
 264-298 Castle Peak Rd
 Tsuen Wan 000000
 Hong Kong

10. The name and title of all company insiders;

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, 5% Control person)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
CHUN FAI LO	CEO/President	Apleichau, Hong Kong	208,926,200	Common	54.806%

PO HUNG RAMEN CHIM	Vice President, Treasurer	Quarry Bay,Hong Kong	56,173,600	Common	14.736%

11. Link to the issuer's most recent Annual Report on OTCMARKETS.COM

<https://www.otcmarkets.com/file/company/financial-report/498339/content>

12. Issuer's Certifications.

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

I, CHUN FAI LO, certify that:

1. I have reviewed this Supplemental Report: Catch-All Information of AOXG;
2. Based on my knowledge, this supplemental disclosure does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this supplemental disclosure; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: November 30, 2025

/s/CHUN FAI LO
Title: CEO